《大行報告》里昂首予康方生物(09926.HK)「買入」評級 內地生物科技首選
里昂發表研究報告指,康方生物(09926.HK)以其管理團隊和免疫腫瘤學(I/O)雙特異性抗體(BsAb)特許經營權表現突出,其商業團隊應該預示著管道銷售的增長。I/O BsAb專營權涵蓋了大範圍的適應症,並處於領先地位。該行在中國生物技術領域中列集團為首選,並首予集團「買入」評級和目標價40.9元。
該行預計,康方生物2021至24年的收入複合年增長率為124.7%,主要受惠於2022年藥物的推出以及Penpulimab(PD-1單抗)的進一步銷售增長。隨著新上市藥品的銷售,該行料2024年集團達至盈虧平衡,料為8,200萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.